Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded Healthcare sector company. As of July 7, 2026, CRNX trades at $84.05 with a market cap of $4.45B and a P/E ratio of -8.39. CRNX moved +98.75% today. Year to date, CRNX is -11.31%; over the trailing twelve months it is +41.04%. Its 52-week range spans $24.10 to $62.53. Analyst consensus is strong buy with an average price target of $85.82. Rallies surfaces CRNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cronos Shares Soar Nearly 100% After-Hours on Vertex’s $10B Acquisition Bid: Cronos shares surged nearly 100% in after-hours trading on news of Vertex Pharmaceuticals' $10 billion acquisition offer. The deal valuation represents a substantial premium to Cronos' previous market capitalization and could significantly reprice its long-term equity value.
| Metric | Value |
|---|---|
| Price | $84.05 |
| Market Cap | $4.45B |
| P/E Ratio | -8.39 |
| EPS | $-5.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.53 |
| 52-Week Low | $24.10 |
| Volume | 1.21M |
| Avg Volume | 0 |
| Revenue (TTM) | $18.07M |
| Net Income | $-496.39M |
| Gross Margin | 0.00% |
12 analysts cover CRNX: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $85.82.